• Anaptys Biosciences Inc., of La Jolla, Calif., raised $33.9 million in a Series B financing led by Novo A/S, with participation from additional investors Frazier Healthcare Ventures, Alloy Ventures, Avalon Ventures, Numenor Ventures, WS Investment Co. and Anaptys board member Nick Lydon. That funding is expected to support continued advancement of the company's technology for therapeutic antibody discovery and optimization and for building a pipeline of product candidates. Heath Lukatch, of Novo A/S, along with James Topper, of Frazier, and J. Leighton Read, of Alloy, will join Anaptys' board.

• BioForce Nanosciences Holdings Inc., of Ames, Iowa, received $500,000 in proceeds from the exercise of Series C warrants issued in a $500,000 August financing. Those warrants entitled the investor to purchase 1 million shares of BioForce's common stock priced at 50 cents each. The company, which develops and commercializes nanotech tools, will use those funds to expand its sales and marketing efforts related to its Nano eNabler system, a device for the deposition and nanoscale manipulation of biomolecules.

• Pharmaxis Ltd., of Sydney, Australia, raised A$11.7 million (US$10.5 million) from its share purchase plan that closed earlier this month. Shareholders were given the opportunity to buy up to $5,000 worth of shares each at the A$3.90 price paid by institutional investors in a A$50 million placement last month. About half the company's shareholders, a total of 2,496, participated in the plan, and Pharmaxis issued about 3 million shares. (See BioWorld Today, Oct. 12, 2007.)